Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 4Polyps 1Ovarian Neoplasms 1Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Malignant Hepatobiliary Neoplasm 1Lung Neoplasms 1Insulin Resistance 1Hereditary Breast and Ovarian Cancer Syndrome 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 50Cyclophosphamide 25Carboplatin 25Gemcitabine 20Cisplatin 19fludarabine 18Nivolumab 17Paclitaxel 16Bevacizumab 15Specimen Handling 14Fluorouracil 11Magnetic Resonance Spectroscopy 10aldesleukin 9Oxaliplatin 9Irinotecan 9Docetaxel 9Biopsy 9olaparib 8Trastuzumab 8durvalumab 7atezolizumab 7Hyperthermic Intraperitoneal Chemotherapy 7Albumin-Bound Paclitaxel 7Taxes 6Leucovorin 6Ipilimumab 6Interleukin-2 6Cetuximab 6Capecitabine 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Telemedicine × Gastrointestinal × Clear all
NCT00609505 2012-02-22

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Duke University

Phase NA Completed
130 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡